CTIS2023-507482-26-00进行中（未招募）1 期
PEACE 8: Combination of darolutamide and stereotactic body radiation therapy in patients with castration resistant prostate cancer and oligometastases on functional imaging. - UC-GTG-2306
nicancer0 个研究点目标入组 195 人开始时间: 2024年2月20日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 195
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- Male
入选标准
- •Patient must have signed a written informed consent prior to any trial specific procedures. When the patient is physically unable to give their written consent, a trusted person of their choice, independent from the investigator or the sponsor, can confirm in writing the patient’s consent., Adequate liver function with bilirubin <3 mg/dL and albumin >2.5 g/dL., Systolic blood pressure <160 mmHg and diastolic blood pressure <100 mmHg, as documented at baseline. Patients with hypertension are eligible if their hypertension is controlled and they meet all other eligibility criteria., Adequate kidney function with a creatinine clearance >30 mL/min (Cockcroft-Gault)., Patient with Eastern Cooperative Oncology group (ECOG) performance status (PS) =1., Patient is willing to use contraceptive during and for at least 1 week after discontinuing darolutamide., Patient affiliated to the social security system (or equivalent according to local regulations for participation in clinical trials)., Patient is willing and able to comply with the protocol for the duration of the trial including undergoing treatment and scheduled visits, and examinations including follow-up., Patients aged =18 years., Patient with histologically confirmed of adenocarcinoma prostate cancer without small cell or pure endocrine features., Patient with a history of local treatment with curative intent for localised prostate cancer, including surgery or radiotherapy., Patients with castration resistant prostate cancer,, Detection of 1 to 5 metastatic sites (pelvic lymph nodes included) on new generation PET using either choline, fluciclovine, or PSMA as tracer;, All metastatic sites must be amenable to stereotactic radiation therapy., Patient with normal haematological function: absolute neutrophil count (ANC) >1.0 x 10^9/L, platelets count =100 x 10^9/L, and haemoglobin =9.0 g/dL., Patient with normal liver function with total bilirubin =1.5 upper limit of normal (ULN) (unless documented Gilbert’s syndrome), ASAT and ALAT =2.5 ULN (=5 ULN in the presence of liver metastases).
排除标准
- •Patient previously treated for metastatic prostate cancer with a novel hormonal agent (NHA), a CYP17 inhibitor, ketoconazole, chemotherapy, or immunotherapy., Patients unable to comply with trial obligations for geographic, social, or physical reasons, or who are unable to understand the purpose and procedures of the trial., Person deprived of their liberty or under protective custody or guardianship., A history of cancer, other than the prostate cancer under study, within the 3 years prior to study inclusion, excluding cured localised cancer such as non-melanomatous skin cancer and non-muscle invasive bladder cancer., Presence of an uncontrolled disease or affection that according to the investigator will hinder compliance with the trial procedures or requires hospitalisation., Known to have active viral hepatitis, active human immunodeficiency virus (HIV) or chronic liver disease at screening, Patients with known allergy or severe hypersensitivity to the study treatment or any of its excipients., Inability and/or difficulty to swallow oral medications., Gastrointestinal disorder or procedure that can be expected to interfere significantly with the absorption of study treatment., Any of the following within 6 months before randomisation: stroke, myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft; congestive heart failure New York Heart Association (NYHA) Class III or IV., Patients participating in another therapeutic trial within the 30 days prior to randomisation.
研究者
相似试验
进行中（未招募）
3 期
Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate CancerProstatic NeoplasmsNCT04736199Bayer669
尚未招募
Unknown
COMPARING EPIDURAL DEXAMETHASONE WITH EPIDURAL TRAMADOL FOR POSTOPERATIVE ANALGESIA IN PATIENTS UNDERGOING ABDOMINAL SURGERIES UNDER GENERAL ANAESTHESIACTRI/2023/06/053841Dr KUDARY NEETHI PRIYANKA
进行中（未招募）
1 期
DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer.CTIS2024-514565-18-00Cancer Trials Ireland1,107
进行中（未招募）
1 期
A clinical research study to investigate whether the addition of a new medication (darolutamide) to standard treatment is better for improving the outcomes for men with localised prostate cancer compared to standard treatment.Clinically localised prostate cancer defined as very high risk, or with very high risk features.MedDRA version: 20.0Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-004818-34-IECancer Trials Ireland1,100
招募中
2 期
enalidomide/dexamethasone Salvage Therapy with stepwise Evatuation for Practical Dose Finding Studyrefractory/resistant multiple myelomaJPRN-UMIN000011568Saitama Medical Center,Saitama Medical University10